Core Insights - Viking Therapeutics has published positive results from the Phase 2 VENTURE clinical trial of VK2735, a dual agonist for weight management, showing weight loss of up to 14.7% after 13 weeks of treatment without a plateau [1][3][4] Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, including VK2735 for obesity treatment [1][9] - The company is also developing VK2809 for lipid and metabolic disorders and VK0214 for X-linked adrenoleukodystrophy [9] Clinical Trials - The ongoing VANQUISH Phase 3 program includes two studies (VANQUISH-1 and VANQUISH-2) evaluating the efficacy and safety of VK2735, with VANQUISH-1 enrolling approximately 4,650 adults and VANQUISH-2 targeting around 1,100 adults with type 2 diabetes [5] - An exploratory maintenance dosing study of VK2735 has also been completed, enrolling about 180 adults [6] Safety and Efficacy - VK2735 demonstrated a favorable safety and tolerability profile in the VENTURE study, with most adverse events reported as mild or moderate [3][4] - The treatment and study discontinuation rates in VK2735 cohorts were comparable to those in the placebo group [3]

Core Insights - Viking Therapeutics has initiated a Phase 1 exploratory maintenance dosing study for VK2735, a dual agonist targeting GLP-1 and GIP receptors, aimed at evaluating various dosing regimens to maintain weight loss achieved through initial treatment [1][2][3] Study Details - The study will involve approximately 180 adults with obesity (BMI ≥ 30 kg/m²) who are otherwise healthy, transitioning from initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks to various maintenance dosing options [2] - Maintenance options include monthly subcutaneous doses, daily oral doses, weekly oral doses, or placebo, with objectives to assess safety, tolerability, and pharmacokinetics [2] - Exploratory endpoints will measure changes in body weight from baseline and from Week 19 to Week 31 [2] Company Overview - Viking Therapeutics focuses on developing novel therapies for metabolic and endocrine disorders, with VK2735 being a key compound in their pipeline [5][6] - The company is also conducting two Phase 3 studies (VANQUISH-1 and VANQUISH-2) to evaluate the efficacy and safety of subcutaneous VK2735 over 78 weeks [3][6] - Viking's research includes other compounds like VK2809 for lipid and metabolic disorders and VK0214 for X-linked adrenoleukodystrophy [6]